Production and purification of polyclonal antibody against F(ab')2 fragment of human immunoglobulin G

Document Type: Original Article

Authors

1 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

3 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Antibodies are essential tools of biomedical and biochemical researches. Polyclonal antibodies are produced against different epitopes of antigens. Purified F(ab')2 can be used for animal’s immunization to produce polyclonal antibodies. Human immunoglobulin G (IgG) was purified by ion exchange chromatography method. In all stages verification method of the purified antibodies was sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Purified IgG was digested by pepsin enzyme and F(ab')2 fragment was purified by gel filtration separation method. For production of polyclonal antibody, rabbit was immunized by purified F(ab')2 and antibody production was investigated by enzyme-linked immunosorbent assay. Purified anti-IgG F(ab')2 was conjugated with fluorescein isothiocyanate. Ion exchange chromatography purification yielded 38 mg of human IgG antibody. The results of SDS-PAGE in reduced and non-reduced conditions showed bands with 25-30 kDa molecular weight (MW) and 50-kDa respectively and a distinct band with 150 kDa MW. The results of non-reduced SDS-PAGE for determining the purity of F(ab')2 fragment showed one band in 90 kDa and a band in 150 kDa MW position. Purification by Ion exchange chromatography method resulted about 12 mg rabbit polyclonal antibody. Flow cytometry showed generated polyclonal antibody had an acceptable activity compared to commercial antibody. Taking together, purified IgG F(ab')2 and polyclonal anti-IgG F(ab')2 are useful tools in biomedical and biochemical researches and diagnostic kits.

Keywords

Main Subjects

  1. Aghebati-Maleki L, Majidi J, Baradaran B, et al. Large scale generation and characterization of anti-Human CD34 monoclonal antibody in ascetic fluid of Balb/c mice. Adv Pharm Bull 2013; 3(1): 211-216.
  2. Maleki LA, Baradaran B, Majidi J, et al. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum Antibodies 2013; 22(1-2): 9-13.
  3. El Bakri A, Nelson PN, Odeh ROA. The state of antibody therapy. Hum Immunol 2010; 71(12): 1243-1250.
  4. Maleki LA, Majidi J, Baradaran B, et al. Production and characterization of murine monoclonal antibody against synthetic peptide of CD34. Hum Antibodies 2013; 22(1-2): 1-8.
  5. Lipman NS, Jackson LR, Trudel LJ, et al. Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources. ILAR J 2005; 46(3): 258-268.
  6. Moradi Z, Majidi J, Aghebati-Maleki L, et al. Polyclonal antibody production against mouse purified IgG2a towards use in basic research. Res Mol Med. 2016; 4(1): 30-35.
  7. Jones R, Landon J. Enhanced pepsin digestion: A novel process for purifying antibody F(ab′)2 fragments in high yield from serum. J Immunoll Methods 2002; 263(1): 57-74.
  8. Bas S, Perneger T, Seitz M, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin anti-bodies and IgM rheumatoid factors. Rheumatology 2002; 41(7): 809-814.
  9. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32(11): 2173-2182.
  10. Lu J, Guo Z, Pan X, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006; 7: 43.
  11. Aghebati-Maleki L, Shabani M, Baradaran B, et al. Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. Biomed Pharmacother 2017; 88: 814-822.
  12. Aghebati-Maleki L, Majidi J, Baradaran B, et al. Generation and characterization of anti-CD34 mono- clonal antibodies that react with hematopoietic stem cells. Cell J 2014; 16(3): 361-366.
  13. Shibaei N, Majidi J, Razavi K, et al. Production and characterization of monoclonal antibody against recombinant virus coat protein CP42. Iran J Allergy Asthma Immunol 2017; 16(1): 60-71.
  14. Sun P, Wang JQ, Zhang YT, et al. Evaluating the immune responses of mice to subcutaneous immunization with Helicobacter pylori urease B subunit. J Anim Sci Biotechnol 2014; 5(1): 14.
  15. Gulati-Sakhuja A, Sears JL, Nunez A, et al. Production of polyclonal antibodies against Pelargonium zonate spot virus coat protein expressed in Escherichia coli and application for immunodiagnosis. J Virol Methods 2009; 160(1): 29-37.
  16. Raoufinia R, Mota A, Nozari S, et al. A methodological approach for purification and characterization of human serum albumin. J Immunoassay Immunochem 2016; 37(6): 623-635.
  17. Sepehr KS, Baradaran B, Majidi J, et al. Development and characterization of monoclonal antibodies against human CD20 in Balb/c mice. Human Antibodies 2012; 21(3-4): 57-64.
  18. Aghebati-Maleki L, Bakhshinejad B, Baradaran B, et al. Phage display as a promising approach for vaccine development. J Biomed Sci 2016; 23(1):66.
  19. Ezzatifar F, Majidi J, Baradaran B, et al. Large scale generation and characterization of anti-Human IgA monoclonal antibody in ascitic fluid of Balb/c mice. Adv Pharm Bull 2015; 5(1): 97-102.
  20. Sineh Sepehr K, Baradaran B, Majidi J, et al. Mass-production and characterization of anti-CD20 monoclonal antibody in peritoneum of Balb/c mice. Adv Pharm Bull 2013; 3(1):109-113.
  21. Wongchuphan R, Tey BT, Tan WS, et al. Purification of rabbit polyclonal immunoglobulin G using anion exchangers. Process Biochem 2011; 46(1): 101-107.
  22. Eivazi S, Majidi J. Production and purification of a polyclonal antibody against purified mouse IgG2b in rabbits towards designing mouse monoclonal isotyping kits. Adv Pharm Bull 2015; 5(1):109-113.
  23. Low D, O’Leary R, Pujar NS. Future of antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848(1): 48-63.
  24. Josic D, Lim YP. Analytical and preparative methods for purification of antibodies. Food Technol Biotechnol 2001; 39(3): 215-226.
  25. Nikolayenko I, Galkin OY, Grabchenko N, et al. Preparation of highly purified human IgG, IgM, and IgA for immunization and immunoanalysis. Ukr Bioorg Acta 2005; 2(2): 3-11.
  26. Valedkarimi Z, Nasiri H, Aghebati-Maleki L, et al. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomed Pharmacother 2017; 95:731-742.
  27. Hanly WC, Artwohl JE, Bennett BT. Review of polyclonal antibody production procedures in mammals and poultry. ILAR J 1995; 37(3): 93-118.
  28. Stiasny K, Aberle JH, Keller M, et al. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis. PLoS One 2012; 7(3): e34145.
  29. Leenaars P, Hendriksen CF, De Leeuw WA, et al. The production of polyclonal antibodies in laboratory animals. The report and recommendations of ECVAM workshop 35. Altern Lab Anim 1999; 27(1): 79-102.
  30. Maleki LA, Baradaran B, Abdolalizadeh J, et al. A unique report: Development of super anti-Human IgG monoclone with optical density over than 3. Adv Pharm Bull 2013; 3(2): 333-337.
  31. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 2012; 526(2): 159-166.
  32. Shin K, Hayasawa H, Lönnerdal B. Purification and quantification of lactoperoxidase in human milk with use of immunoadsorbents with antibodies against recombinant human lactoperoxidase. Am J Clin Nutr 2001; 73(5): 984-989.
  33. Aghebati-Maleki L, Younesi V, Jadidi-Niaragh F, et al. Isolation and characterization of anti ROR1 single chain fragment variable antibodies using phage display technique. Hum Antibodies 2017; 25(1-2): 57-63.
  34. Aghebati-Maleki L, Younesi V, Baradaran B, et al. Antiproliferative and apoptotic effects of novel anti-ROR1 single-chain antibodies in hematological malignancies. SLAS Discov 2017; 22(4): 408-417.
  35. Kairemo KJ, Ljunggren K, Wahlström T, et al. Correlation of beta-camera imaging and immunohistochemistry in radioimmunotherapy using 90Y-labeled monoclonal antibodies in ovarian cancer animal models. Cell Biophys 1994; 24(1-3): 293-300.
  36. Oba R, Orihara K, Kumagai T, et al. Reevaluation of quantitative flow cytometric analysis for TLR2 on monocytes using F(ab′)2 fragments of monoclonal antibodies. Cytom Part A 2011; 79(4): 247-255.